spectrophotometer. Fluorescence spectra of compounds were measured on a LS55 fluorescence spectrometer (Perkin Elmer, Santa Clara, CA, USA). TEM images were collected on a JEOL 2100 cryo TEM.
Synthesis of CPT-S-S-CPT.
CPT (2.0 mmol, 696.7 mg) was suspended in anhydrous DCM (30 mL), followed by addition of triphosgene (0.8 mmol, 237.4 mg) and 4-(dimethylamino)pyridine (DMAP, 2.0 mmol, 244.3 mg). The mixture was stirred at room temperature for 4 h until the solution became clear, at which time point 2-hydroxyethyl disulfide (0.8 mmol, 123.4 mg) in THF/DCM (1/3, v/v, 2 mL) was added in one portion. The reaction mixture was stirred at room temperature for another 24 h. Solvent was removed under reduced pressure and the crude product was purified by silica gel column chromatography using ethyl acetate to ethyl acetate/methanol (9/1, v/v) as the eluent. A light yellow solid was obtained (62% yield Synthesis of N-propargyl-2,3-dibromomaleimide. 2,3-dibromomaleimide (1.0 mmol, 254.9 mg) and propargyl bromide (2.5 mmol, 297.4 mg) were dissolved in acetone (60 mL), followed by addition of potassium carbonate (4.0 mmol, 552.8 mg). The mixture was stirred at room temperature for 48 h. The precipitate was filtrated off, and the solvent was removed. The crude product was purified by silica gel column chromatography using hexane/ethyl acetate (1/1, v/v) as the eluent (50% yield Preparation of (CPT) 2 -Mal-PEG 1k NPs. (CPT) 2 -Mal-PEG 1k in DMF (10 mg/mL, 100 μL) was stirred vigorously and slowly added nanopure water (4 mL) dropwise in 30 min. After the addition of nanopure water was complete, the solution was stirred for another 4 h prior to dialysis against DI water for 48 h.
General procedures for the synthesis of 2,3-dithiomaleimides. 2,3-dibromomaleimide (1 molar equivalent) was added to a mixture of thiol (2.1 molar equivalents) and triethylamine (2.1 molar equivalents) in anhydrous methanol, and the mixture was stirred at room temperature for 2 h-6 h, at which point TLC should show complete consumption of 2,3-dibromomaleimide.
GSH-induced degradation of (CPT) 2 -Mal-PEG 1k
(1) Fluorescence measurements: (CPT) 2 -Mal-PEG 1k in methanol (50 μg/mL, 2.5 mL) was added to a cuvette. GSH was added with a final concentration of 5 mM. The mixture was incubated at 37 o C (100 rpm). At selected time points, the solution was sent for fluorescence measurement on a fluorescence spectrometer.
(2) Determination of CPT release kinetics by HPLC: (CPT) 2 -Mal-PEG 1k in methanol (50 μg/mL, 1 mL) was added to a HPLC vial. GSH was added with a final concentration of 5 mM and the mixture was incubated at 37 o C (100 rpm). At selected time points, the sample was run on HPLC. A mixture of acetonitrile and water (containing 0.1% TFA) at a volume ratio of 2:3 was used as the mobile phase. A fluorescence detector (excitation wavelength: 370 nm, emission wavelength: 430 nm) and a PDA detector (190-800 nm) were used. The flow rate was set at 1.5 mL/min. Released CPT was quantified by the standard curve of free CPT.
GSH-induced degradation of (CPT) 2 -Mal-PEG 1k NPs
(1) Fluorescence and DLS measurements: (CPT) 2 -Mal-PEG 1k NPs in PBS (100 μg/mL, 2.5 mL) in a cuvette was incubated with or without the presence of GSH (5 mM) at 37 o C (100 rpm).
At selected time points, the solution was sent for fluorescence measurement on a fluorescence spectrometer. After the fluorescence measurement, the same solution was measured by DLS to determine the size and the count rate of NPs.
(2) Determination of CPT release kinetics by HPLC: (CPT) 2 -Mal-PEG 1k NPs were dispersed in PBS (100 μg/mL, 2 mL, pH = 7.4) and transferred into a dialysis bag. The dialysis bag was then immersed in PBS (40 mL) with or without GSH (1 mM or 5 mM) and incubated at 37 o C (100 rpm). At selected time points, 1 mL aliquot of the dialysis medium was withdrawn and brought to pH = 2 with phosphoric acid (85%, 10 μL) prior to HPLC measurement and the same amount of fresh medium was added. A mixture of acetonitrile and water (containing 0.1% TFA) at a volume ratio of 2:3 was used as the mobile phase for HPLC measurements. A fluorescence detector (excitation wavelength: 370 nm, emission wavelength: 430 nm) and a PDA detector (190-800 nm) were used. The flow rate was set at 1.5 mL/min. Released CPT was quantified by the standard curve of free CPT.
MTT study. In vitro cytotoxicity of (CPT) 2 -Mal-PEG 1k NPs and free CPT was measured by MTT assay. LS174T colon cancer cells were seeded in a 96-well plate at an initial density of 4×10 3 cells/well, allowed to attach for 24 h and treated with free CPT or NPs at various CPT concentrations for 48 h at 37 o C. Cells without NP or free CPT treatment were used as control.
Free CPT of various concentrations were first dissolved in DMSO and then diluted with a 10-fold volume of PBS prior to adding to the cells. The MTT assay was performed by following the standard procedures.
Influence of GSH-OEt on the cytotoxicity of (CPT) 2 -Mal-PEG 1k NPs and free CPT against LS174T cells. LS174T cells were seeded in a 96-well plate with an initial density of 4×10 3 cells/well and allowed to attach for 24 h. GSH-OEt with a final concentration of 10 mM was added and incubated with the cells for 4 h. Then the medium was replaced with fresh medium, followed by addition of (CPT) 2 -Mal-PEG 1k NPs or free CPT at various CPT concentrations.
Cells were further incubated for 48 h. Cell viability was determined by the MTT assay.
TEM measurements. TEM samples were prepared on 200 mesh carbon film supported copper grids. One drop of the NP solution (~ 10 µL) (0.25-0.5 mg/mL) was placed on the grid and allowed to stand for 10 min. Filter paper was then used to remove the residual solution. The resulting sample was imaged using JEOL 2100 Cryo TEM at 200 kV. 
